2 (2')

Rivulobirin E and Rivulotririn C from *Pleurospermum rivulorum*

Masahiko TANIGUCHI,^{*a*} Yong-Qing XIAO,^{*b*} Xiao-Hong LIU,^{*b*} Akiko YABU,^{*a*} Yousuke HADA,^{*a*} Lian-Qing GUO,^{*c*} Yasushi YAMAZOE,^{*c*} and Kimiye BABA^{*,*a*}

Osaka University of Pharmaceutical Sciences,^a 4–20–1 Nasahara, Takatsuki, Osaka 569–1094, Japan, Institute of Chinese Materia Medica, China Academy of Traditional Chinese Medicine,^b Beijing 100700, China, and Faculty of Pharmaceutical Sciences, Tohoku University,^c Aramaki-Aoba, Aoba-ku, Sendai 980–8578, Japan. Received February 25, 1999; accepted April 9, 1999


Two new condensed furanocoumarins, the dimer rivulobirin E and the trimer rivulotririn C (1 and 2) were isolated from the underground part of *Pleurospermum rivulorum* (Umbelliferae) and their structures established by spectral means.

Key words *Pleurospermum rivulorum*; rivulobirin E; rivulotririn C; Umbelliferae

In the course of our studies on the chemical constituents of Umbelliferae species we reported the isolation of new bi-

 ^{1}H

Table 1. ¹H and ¹³C NMR Data for Rivurobirin E (1) in CDCl₃



coumarins, rivulobirins A—D, and spirotricoumarins, rivulotririns A and B. $^{1-3)}$ In the present study, we isolated two

new condensed furanocoumarins, rivulobirin E(1) and rivulotririn C(2) from the same coumarin fraction by repeated

Fig. 1. HMBC Correlations of 1

(2')		160.21		
(3')	6.33 d (9.6)	114.67	Table 2. ¹ H NMR Data for Rivulotririn C (2) in $CDCl_3$	
4')	7.74 br d (9.6)	144.15		•
'a)		116.37	Н	2
(5')	7.34 br s	113.06	2	5 77 1 (0 ()
5')		126.04	3	5.77 d (9.6)
7')		147.49	4	6.85 d (9.6)
3')		131.52^{a}	5	7.09 s
u (8'a)		142.90	9	7.54 d (2.1)
(9')	7.68 d (2.2)	146.63^{b}	10	6.68 d (2.1)
(10')	6.81 d (2.2)	106.69 ^c)	11	4.60 dd (10.3, 2.7)
	4.40 dd (10.1, 5.3)	75.27^{d}		4.31 dd (10.3, 7.3)
	4.55 dd (10.1, 4.2)		12	3.74 ddd (7.3, 4.6, 2.7)
	4.03 dd (5.3, 4.2)	77.90	14	1.26 s
		72.09	15	1.28 s
	1.29 s	24.76	12-OH	3.55 d (4.6)
	1.36 s	26.53	13-OH	2.80 s
Н	2.25 s	20100	3'	5.72 d (9.6)
2)	2120 5	160.33	4'	6.85 d (9.6)
	6.31 d (9.6)	114.43	5'	7.08 s
5) 5)	7.70 br s (9.6)	144.25	9'	7.53 d (2.1)
(4a)	1.10 013 (5.0)	116.28	10'	6.68 d (2.1)
(44)	7.29 br s	113.33	11'	4.61 dd (10.1, 6.2)
(6)	7.29 01 8	125.90		4.43 dd (10.1, 6.2)
(0)		147.96	12'	4.85 dd (6.2, 6.2)
		131.60^{a}	14'	1.41 s
(8)		143.26	15'	1.72 s
a (8) (9)	7(74(22))	143.26 $146.70^{b)}$	3"	6.35 d (9.6)
	7.67 d (2.2)		3 4″	7.73 d (9.6)
(10)	6.77 d (2.2)	106.65^{c}	4 5″	7.35 s
	4.55 dd (10.2, 8.6)	75.21 ^{<i>d</i>})	9″	7.53 d (2.2)
	4.84 dd (10.2, 2.7)			· · · ·
	4.13 dd (8.6, 2.7)	76.27	10"	6.77 d (2.2)
,		78.02	11"	4.77 dd (10.1, 5.9)
'	1.44 s	24.18	10"	4.51 dd (10.1, 6.6)
, ,	1.49 s	22.69	12"	4.83 dd (6.6, 5.9)
'-OH	3.77 s		14"	1.40 s
			15″	1.69 s

¹³C

160.21

Chemical shifts are in δ values and followed by multiplicities and J values (in Hz). a-d) Assignment may be reversed.

* To whom correspondence should be addressed.


Chemical shifts are in δ values and followed by multiplicities and J values (in Hz).

© 1999 Pharmaceutical Society of Japan

chromatographic separation. This communication deals with the structure elucidation of **1** and **2**.

Rivulobirin E (1), a colorless viscous oil, was assigned the molecular formula $C_{32}H_{30}O_{11}$ ($[M+H]^+$ m/z 591.1857) by HR-SIMS. The NMR (Table 1) signal pattern of 1 is closely related to those of rivulobirin A except for the presence of signals due to two pairs of the 3-methylbutyl-1,2,3-trioxy group instead of the signals due to a 3-methyl-3-butenyl-1,2-dioxy group and a 3-methylbutyl-1,2,3-trioxy group. Thus 1 was assumed to be a *tert*-O-heraclenyl-heraclenol. The entire structure of 1 was determined by extensive 2D-NMR experiments [¹H-¹H COSY, HMQC, HMBC (Fig. 1) and NOESY spectra]. The determination of the absolute configuration of C-12' in 1 was carried out by the modified Mosher's method. Further more, the configuration of the C-12 position was as-

Table 3. ¹³C NMR Data for Rivulotririn C (2) in CDCl₃



sumed to be R based on the fact that C-12' in **1** and C-12 in furanocoumarins previously isolated from this plant have the same configuration.

Rivulotririn C (2), a colorless viscous oil, was assigned the molecular formula $C_{48}H_{44}O_{16}$ ([M]⁺ *m/z* 876.2629) by HR-EI-MS. The ¹H-NMR (Table 2) spectrum of 2 showed the presence of three C-8-substituted linear-type furanocoumarin units and three sets of a 3-methylbutyl-1,2,3-trioxy group. Thus 2 was presumed to be a structure resulting from the condensation of three heraculenol units. However, in ¹³C-NMR (Table 3) only one lactone carbonyl carbon signal and two orthoester carbon signals were observed, indicating that two of three lactone moieties were replaced by the spiro form in 2. The entire structure including the relative configuration was determined by the analysis of 2D-NMR experiments





Fig. 2. HMBC Correlations of 2



Chemical shifts are in δ values. a-h Assignment may by reversed

Fig. 3. NOE Correlations of 2

[¹H-¹H COSY, HMQC, HMBC (Fig. 2) and NOESY (Fig. 3) spectra]. Compound **2** is the first example of a trifura-nocoumarin bearing two orthoester moieties.

Recently, several components have been isolated from grapefruit juice which showed strong inhibitory effects on CYP3A activity and their structure identified them as furanocoumarin derivatives.⁴⁾ Thus the furanocoumarin derivatives isolated from Umbelliferous plants including *P. rivulorum* were also tested. As a result, the most linear furanocoumarins examined showed inhibitory effects on CYP3A activity. The dimer derivatives rivulobirin A, C, and D, and the trimer derivative, rivulotririn A showed especially strong inhibitory effects, with an IC_{50} value similar to that of the typical CYP3A inhibitor ketoconazole. Further biological studies on those compounds are now in progress, and the details will be reported elsewhere.

REFERENCES

- Xiao Y.-Q., Liu X.-H., Taniguchi M. and Baba K., *Phytochemistry*, 45, 1275—1277 (1997).
- Taniguchi M., Xiao Y.-Q., Liu X.-H., Yabu A., Hada Y. and Baba K., *Chem. Pharm. Bull.*, 46, 1065–1067 (1998).
- Taniguchi M., Xiao Y.-Q., Liu X.-H., Yabu A., Hada Y. and Baba K., Chem. Pharm. Bull., 46, 1946—1947 (1998).
- Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M. and Yamazoe Y., *Pharmacogenetics*, 7, 391–396 (1997).